Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 5/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008113 | 0.96 | APEX1 (0.49) | APEX1PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL4008006 | 0.86 | YTHDC1 (0.45) | APEX1PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL4013654 | 0.84 | APEX1 (0.50) | APEX1LGALS8LGALS3 | |
| SCHEMBL4007111 | 0.83 | APEX1 (0.52) | APEX1LGALS8LGALS3KCNH2JAK2 | |
| SCHEMBL6556007 | 0.83 | NTRK1 (0.39) | APEX1PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL4014969 | 0.83 | FLT3 (0.51) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL4005400 | 0.82 | APEX1 (0.46) | APEX1PRKAG1PRKAA1PRKAB1PRKAB2 | |
| SCHEMBL4006545 | 0.81 | APEX1 (0.50) | APEX1LGALS8LGALS3KCNH2 | |
| SCHEMBL4008318 | 0.81 | APEX1 (0.50) | APEX1LGALS8LGALS3KCNH2JAK2 | |
| SCHEMBL4008126 | 0.81 | NTRK1 (0.44) | PRKAG1PRKAA1PRKAB1NTRK1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | APEX1 2215/4885PRKAG1 333/4885PRKAA1 137/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | APEX1 2168/4885PRKAG1 271/4885PRKAA1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.